Alva Review-Courier -

AP Medical Writer 

AstraZeneca wins US approval for lymphoma drug


November 1, 2017

U.S. regulators have approved a new treatment for people with a rare form of non-Hodgkin lymphoma.

The Food and Drug Administration on Tuesday granted accelerated approval to AstraZeneca PLC's Calquence for people with mantle cell lymphoma after chemotherapy or other treatments fail. The British drugmaker is now conducting further testing required by the FDA to confirm the drug's benefits and risks.

Mantle cell lymphoma is a blood cancer that usually strikes middle-aged people and the elderly. By the time it's diagnosed, it usually has spread to the lymph nodes, bone marrow and other organs...

For access to this article please sign in or subscribe.


Reader Comments(0)


Our Family of Publications Includes:

Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2021